Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): D ata from randomized controlled trials

2017 ◽  
Vol 19 (9) ◽  
pp. 1233-1241 ◽  
Author(s):  
Matteo Monami ◽  
Besmir Nreu ◽  
Alessia Scatena ◽  
Barbara Cresci ◽  
Francesco Andreozzi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Randomized Controlled Trials ◽  
Controlled Trials ◽  
Safety Issues ◽  
Receptor Agonists ◽  
Randomized Controlled ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: a meta‐analysis of randomized controlled trials

2021 ◽  
Author(s):  
Luis E. Simental‐Mendía ◽  
Adriana Sánchez‐García ◽  
Enrique Linden‐Torres ◽  
Mario Simental‐Mendía
Keyword(s):  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Receptor Agonists ◽  
Randomized Controlled ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials

Endocrine ◽  
2014 ◽  
Vol 48 (1) ◽  
pp. 107-115 ◽  
Author(s):  
Bin Su ◽  
Hui Sheng ◽  
Manna Zhang ◽  
Le Bu ◽  
Peng Yang ◽  
...  
Keyword(s):  
Randomized Controlled Trials ◽  
Bone Fractures ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Receptor Agonists ◽  
Randomized Controlled ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Erratum to: Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials

2017 ◽  
Vol 54 (11) ◽  
pp. 1069-1071
Author(s):  
Ilaria Dicembrini ◽  
Besmir Nreu ◽  
Alessia Scatena ◽  
Francesco Andreozzi ◽  
Giorgio Sesti ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Receptor Agonists ◽  
Randomized Controlled ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document